Nasal spray could zap COVID-19 virus in the nose
NCT ID NCT05799521
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a nasal spray called Optate in 24 adults with mild COVID-19. The spray aims to lower virus levels in the nose and improve symptoms like congestion. Participants receive either Optate or a placebo, and researchers measure changes in virus levels and symptom scores one hour and 24 hours after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Optate (glycine and alkaline buffer) nasal spray
What this could lead to
If it works, this could provide a simple, at-home nasal spray to lower virus levels and ease symptoms for people with mild COVID-19.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The treatment is tested only for mild cases and may not work for severe illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States